The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors.
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma
Consulting or Advisory Role - Actym Therapeutics; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; EMD Serono; ImmunoGenesis; Innovent Biologics; Janssen Oncology; Merck; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Mohamad Adham Salkeni
Employment - Next Oncology; Virginia Cancer Specialists
Stock and Other Ownership Interests - Next Oncology
Honoraria - Healthcasts
Research Funding - 1ST Biotherapeutics (Inst); Agenus (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); CrystalGenomics (Inst); IDEAYA Biosciences (Inst); Inmune Bio (Inst); Kronos Bio (Inst); MBrace Therapeutics (Inst); OncoResponse (Inst); Oncternal Therapeutics (Inst); Prelude Therapeutics (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Tarus Therapeutics (Inst)
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; Exelixis; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Jaspreet Singh Grewal
Honoraria - Curio Science; Eisai
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bayer; BMS GmbH & Co. KG; Ipsen
Expert Testimony - Monsanto
 
William J Tester
No Relationships to Disclose
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Pfizer/EMD Serono; Sanofi; Tolmar Therapeutics
Speakers' Bureau - AstraZeneca; Bayer; Genentech/Roche; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
Daniel Frigo
Employment - Biocity Biopharmaceuticals (I); Hummingbird (I)
Leadership - Biocity Biopharmaceuticals (I); Hummingbird (I)
Stock and Other Ownership Interests - ALMS Therapeutics (I); Barricade Therapeutics (I); Biocity Biopharmaceuticals (I); Hinova Pharmaceuticals (I); Hummingbird (I); MAIA Biotechnology (I)
Patents, Royalties, Other Intellectual Property - Frigo, D.E., A.R. Means and D.P. McDonnell. “CaMKK-? as a Target for Treating Cancer”. United States Patent 9999620. Issued 6/17/2018. “Novel Therapeutic Targets in the Androgen Receptor Signaling Pathway”. European Patent 2606130. Issued 3/13/2019.
 
Theocharis Panaretakis
No Relationships to Disclose
 
Desa Rae Electa Pastore
Employment - Portage Biotech; Tarus Therapeutics; Vaccinex
Stock and Other Ownership Interests - Portage Biotech; Portage Biotech; Vaccinex
Consulting or Advisory Role - Portage Biotech; Tarus Therapeutics; Vaccinex
 
Robert A. Kramer
Employment - Portage Biotech
Leadership - Portage Biotech
Stock and Other Ownership Interests - Portage Biotech
Consulting or Advisory Role - NeoTx
 
George Green
Consulting or Advisory Role - Flare Therapeutics; Normunity; Portage Biotech; Spark Therapeutics
 
Justin P. Fairchild
Employment - Georgiamune; Portage Biotech
 
Ian B. Walters
Employment - Intensity Therapeutics; Portage Biotech
Leadership - Intensity Therapeutics; Portage Biotech
Stock and Other Ownership Interests - Intensity Therapeutics; Portage Biotech
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Clinical Care Options
Consulting or Advisory Role - Abbvie (Inst); BostonGene (Inst); BostonGene (Inst); BridgeBio Pharma (Inst); EMD Serono; Fujifilm (Inst); Inspirna (Inst); Jubilant Pharmaceuticals (Inst); Merck (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Sanofi (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Teon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); American Society of Clinical Oncology (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biomea Fusion (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Centessa Pharmaceuticals (Inst); Ciclomed (Inst); Conjupro Biotherapeutics (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); Eikon Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harbour BioMed (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunitas (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kineta (Inst); Kolltan Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); MD Anderson Cancer Center (Inst); MedImmune (Inst); Merck (Inst); Metabomed (Inst); Millennium (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); National Institute of Health (NIH) (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); OncoMed (Inst); Oncorus (Inst); Oncothyreon (Inst); Phanes Therapeutics (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Roche (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tango Therapeutics (Inst); Tarus Therapeutics (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst); Zhuhai Yufan Biotechnologies (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute; Synthorx/Sanofi
 
Sumit Kumar Subudhi
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Amgen; Apricity Health; Arcus Biosciences,; AstraZeneca; Baird; Bayer; Boxer Capital; Breaking Data; Bristol-Myers Squibb; Cancer Expert Now; ChemoCentryx; Clinical Comms Group; Dava Oncology; Dendreon; InProTher Janssen; Janssen; Javelin Oncology; Kahr Medical Ltd; MD Education; Merck; OncLive (owned by Intellisphere, LLC); Pfizer; Polaris; Portage Biotech; Regeneron
Research Funding - AstraZeneca; Bristol-Myers Squibb; Janssen; Regeneron
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Regeneron